New Competing Pacemaker Products and Low-Price Strategies
First written in FY2023-Q1. 9 of 11 entries say "Worsened", first in FY2023-Q2. Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- 2026-07-30WorsenedEarnings
「Although the impact of lower unit prices resulting from the reimbursement price revision was limited for pacemaker-related products, they performed poorly due to the impact of competitors’ leadless pacemakers.」
The impact of competitors’ leadless pacemakers on sales continued, and pacemaker-related products remained weak. - FY2026WorsenedAnnual report
「Pacemakers performed poorly, affected by competitors’ leadless pacemakers.」
The continuing expansion of competitors' leadless pacemakers into new cases intensified the competitive risk, with the company's pacemaker sales remaining sluggish. - 2026-05-07WorsenedEarnings
「Pacemakers performed poorly, affected by competitors’ leadless pacemakers.」
The company again indicated that its pacemaker sales remained weak due to the impact of competitors’ leadless pacemakers. - FY2025WorsenedAnnual report
「As competitors' leadless pacemakers expanded into new cases, sales of the company's pacemakers remained sluggish.」
In the pacemaker field, competitors' leadless pacemakers expanded into new cases, causing the company's sales to weaken. - FY2025-H1WorsenedAnnual report
「As competitors' leadless pacemakers expanded into new cases, sales of the company's pacemakers remained sluggish.」
Competitors' leadless pacemakers expanded into new cases, causing sales of the company's pacemakers to weaken. - FY2024-Q2WorsenedAnnual report
「Pacemaker revenue increased 0.2% year on year. Sales were strong in the first quarter but sluggish in the second quarter because of the impact of competitors' new products. As a result, the market share for the six-month cumulative period remained almost unchanged.」
After strong sales in the first quarter, sales were sluggish in the second quarter because of competitors' new products, leaving the market share for the six-month cumulative period almost unchanged. - FY2024-Q1MitigatedAnnual report
「As the effects of competitors' new products and low-price sales began to subside, the company increased face-to-face sales using catheters and other products that support proper lead placement during surgery. As a result, it secured a market share slightly above the previous fiscal year's level.」
The effects of competitors' new products and low-price sales subsided, and increased face-to-face sales using catheters lifted the pacemaker market share slightly above the previous fiscal year's level. - FY2023WorsenedAnnual report
「The pacemaker business remained challenging because of intensifying competition. The introduction of SSPC (Site Selective Pacing Catheter), which assists with pacemaker lead placement, kept sales volume at approximately the previous fiscal year's level, but revenue fell substantially because of a significant decline in reimbursement prices.」
Although the introduction of SSPC kept sales volume at approximately the previous fiscal year's level, intensifying competition and a substantial decline in reimbursement prices led to a significant decrease in pacemaker revenue. - FY2023-Q3WorsenedAnnual report
「Although measures including the introduction of SSPC (Site Selective Pacing Catheter), which assists with pacemaker lead placement, had a certain effect, pacemaker sales volume declined year on year. Revenue decreased substantially as selling prices fell following a significant decline in reimbursement prices.」
Despite measures including the introduction of SSPC, pacemaker sales volume declined year on year, while the substantial decline in reimbursement prices and resulting lower selling prices led to a significant decrease in revenue. - FY2023-Q2WorsenedAnnual report
「The pacemaker business remained challenging, affected by competitors' new products and low-price strategies. Although the overall market showed a gradual increase in volume, the company's sales volume remained at approximately the same level as in the previous year. In addition, reimbursement prices for the company's major pacemaker models were reduced substantially, lowering selling prices and causing revenue to decline year on year.」
In addition to competitors' new products and low-price strategies, the reduction in reimbursement prices for major models lowered selling prices. Sales volume remained at approximately the same level as in the previous year, while revenue declined. - FY2023-Q1First statedAnnual report
「The pacemaker business remained challenging, affected by competitors' new products and low-price strategies. Although the overall market showed a gradual increase in volume, the company's sales volume remained at approximately the same level as in the previous year. In addition, reimbursement prices for the company's major pacemaker models were reduced substantially, lowering selling prices and causing revenue to decline year on year.」
The pacemaker business continued to be affected by competitors' new products and low-price strategies. Sales volume remained sluggish, and the decline in selling prices contributed to a 6.8% year-on-year decrease in revenue.